INFOGRAPHIC: Going into 2022, there were high expectations for deal-making, but industry continues to face significant headwinds. Scrip reviewed M&A and alliance activity for the first half of the year to track how business development is shaping up in 2022.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Pursuing first-in-class molecular glue degraders using undruggable targets could eventually help Degron Therapeutics land sizable asset-based deals, CEO Lily Zou tells Scrip.
Kymera will move KT-621 into Phase II trials later this year based on compelling data in healthy volunteers, validating the company’s protein-degradation platform.
All eyes are on the upcoming readout of BPL-003 for treatment-resistant depression.
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
BMS is guaranteeing BioNTech at least $3.5bn to share development costs and potential profits on the Phase III bispecific, to compete with Summit, Merck and Pfizer.
Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.
But the French major is still keen on early-stage M&A.
